MX2023002420A - Métodos para la prevención del embolismo por cristales de colesterol con ciclodextrinas. - Google Patents
Métodos para la prevención del embolismo por cristales de colesterol con ciclodextrinas.Info
- Publication number
- MX2023002420A MX2023002420A MX2023002420A MX2023002420A MX2023002420A MX 2023002420 A MX2023002420 A MX 2023002420A MX 2023002420 A MX2023002420 A MX 2023002420A MX 2023002420 A MX2023002420 A MX 2023002420A MX 2023002420 A MX2023002420 A MX 2023002420A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- embolization
- risk
- preventing
- individual
- Prior art date
Links
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 title abstract 8
- 235000012000 cholesterol Nutrition 0.000 title abstract 4
- 239000013078 crystal Substances 0.000 title abstract 4
- 230000010102 embolization Effects 0.000 title abstract 2
- 229920000858 Cyclodextrin Polymers 0.000 title 1
- 229940097362 cyclodextrins Drugs 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 abstract 2
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 210000002381 plasma Anatomy 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063071243P | 2020-08-27 | 2020-08-27 | |
| PCT/US2021/048075 WO2022047244A1 (en) | 2020-08-27 | 2021-08-27 | Methods for the prevention of cholesterol crystal embolization with cyclodextrins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023002420A true MX2023002420A (es) | 2023-07-11 |
Family
ID=80352440
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023002420A MX2023002420A (es) | 2020-08-27 | 2021-08-27 | Métodos para la prevención del embolismo por cristales de colesterol con ciclodextrinas. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230302042A1 (https=) |
| EP (1) | EP4203973A4 (https=) |
| JP (1) | JP2023543132A (https=) |
| KR (1) | KR20230096976A (https=) |
| CN (1) | CN116635007A (https=) |
| AU (1) | AU2021331485A1 (https=) |
| BR (1) | BR112023003490A2 (https=) |
| CA (1) | CA3190764A1 (https=) |
| IL (1) | IL300881A (https=) |
| MX (1) | MX2023002420A (https=) |
| WO (1) | WO2022047244A1 (https=) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4877778A (en) * | 1987-07-01 | 1989-10-31 | The Children's Medical Center Corporation | Method of enhancing lipophile transport using cyclodextrin derivatives |
| MX371073B (es) * | 2012-04-13 | 2020-01-15 | L&F Res Llc | Método para utilizar ciclodextrina. |
-
2021
- 2021-08-27 MX MX2023002420A patent/MX2023002420A/es unknown
- 2021-08-27 WO PCT/US2021/048075 patent/WO2022047244A1/en not_active Ceased
- 2021-08-27 KR KR1020237010391A patent/KR20230096976A/ko not_active Withdrawn
- 2021-08-27 US US18/043,009 patent/US20230302042A1/en active Pending
- 2021-08-27 BR BR112023003490A patent/BR112023003490A2/pt not_active Application Discontinuation
- 2021-08-27 IL IL300881A patent/IL300881A/en unknown
- 2021-08-27 CA CA3190764A patent/CA3190764A1/en active Pending
- 2021-08-27 JP JP2023513678A patent/JP2023543132A/ja active Pending
- 2021-08-27 CN CN202180066571.3A patent/CN116635007A/zh active Pending
- 2021-08-27 EP EP21862878.2A patent/EP4203973A4/en active Pending
- 2021-08-27 AU AU2021331485A patent/AU2021331485A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230096976A (ko) | 2023-06-30 |
| CA3190764A1 (en) | 2022-03-03 |
| EP4203973A4 (en) | 2024-08-21 |
| US20230302042A1 (en) | 2023-09-28 |
| BR112023003490A2 (pt) | 2023-05-09 |
| JP2023543132A (ja) | 2023-10-13 |
| IL300881A (en) | 2023-04-01 |
| CN116635007A (zh) | 2023-08-22 |
| EP4203973A1 (en) | 2023-07-05 |
| AU2021331485A1 (en) | 2023-03-23 |
| WO2022047244A1 (en) | 2022-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Fillingham et al. | Tranexamic acid in total joint arthroplasty: the endorsed clinical practice guides of the American association of hip and knee surgeons, American society of regional anesthesia and pain medicine, American academy of orthopaedic surgeons, hip society, and knee society | |
| MX2023002419A (es) | Metodos para el tratamiento del embolismo por cristales de colesterol con ciclodextrinas. | |
| Fuji et al. | Prevention of postoperative venous thromboembolism in Japanese patients undergoing total hip or knee arthroplasty: two randomized, double-blind, placebo-controlled studies with three dosage regimens of enoxaparin | |
| Ker et al. | Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis | |
| Simard et al. | Low-dose intravenous heparin infusion in patients with aneurysmal subarachnoid hemorrhage: a preliminary assessment | |
| Konstan | Ibuprofen therapy for cystic fibrosis lung disease: revisited | |
| Shinohara et al. | II. Cerebral infarction/transient ischemic attack (TIA) | |
| Sveinsson et al. | Intra-arterial mechanical thrombectomy: an effective treatment for ischemic stroke caused by endocarditis | |
| Bennett et al. | Emerging indications for hyperbaric oxygen | |
| Yu et al. | Safety and efficacy of tranexamic acid in total knee arthroplasty | |
| MX2023002420A (es) | Métodos para la prevención del embolismo por cristales de colesterol con ciclodextrinas. | |
| Mathews et al. | Surgery for hemophilia in developing countries | |
| Jazayeri et al. | Reevaluating the role of heparin during mechanical thrombectomy for acute ischemic stroke: Increased risks without functional benefit | |
| Bonarelli et al. | Dabigatran etexilate and LMWH for the prevention of venous thromboembolism in 532 patients undergoing hip surgery | |
| Wu et al. | Severe chemosis and treatment following fronto-orbital advancement surgery for Crouzon syndrome: a case report | |
| Colwell et al. | Ximelagatran for the prevention of venous thromboembolism following elective hip or knee replacement surgery | |
| Rosencher et al. | Should new oral anticoagulants replace low-molecular-weight heparin for thromboprophylaxis in orthopaedic surgery? | |
| Psevdos Jr et al. | Acute renal failure in patients with AIDS on tenofovir while receiving prolonged vancomycin course for osteomyelitis | |
| Maigrot et al. | Outcomes after left atrial appendage clip placement during cardiac surgery: a nationwide analysis | |
| Fuentes-Garcia et al. | Prothrombin complex concentrate in the treatment of multitransfusion dilutional coagulopathy in a paediatric patient | |
| Velusamy | Comparison of treatment outcome of antihypertensive drugs in the management of pregnancy induced hypertension | |
| Galanis et al. | New oral anticoagulants: prevention of VTE in phase III studies in total joint replacement surgery and the hospitalized medically-ill patients | |
| Aledort | The ongoing imperative for immune tolerance induction in inhibitor management. | |
| DeVee et al. | Management of acute ischemic stroke: A review of pertinent guideline updates | |
| Tenali | MUCORMYCOSIS: ASSESSMENT OF RISK FACTORS IN A SUBJECT SUFFERING FROM CONGENITAL HAEMOPHILIA |